These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

723 related articles for article (PubMed ID: 19716961)

  • 1. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials.
    Fabbri LM; Calverley PM; Izquierdo-Alonso JL; Bundschuh DS; Brose M; Martinez FJ; Rabe KF;
    Lancet; 2009 Aug; 374(9691):695-703. PubMed ID: 19716961
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials.
    Calverley PM; Rabe KF; Goehring UM; Kristiansen S; Fabbri LM; Martinez FJ;
    Lancet; 2009 Aug; 374(9691):685-94. PubMed ID: 19716960
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial.
    Martinez FJ; Calverley PM; Goehring UM; Brose M; Fabbri LM; Rabe KF
    Lancet; 2015 Mar; 385(9971):857-66. PubMed ID: 25684586
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial.
    Decramer M; Celli B; Kesten S; Lystig T; Mehra S; Tashkin DP;
    Lancet; 2009 Oct; 374(9696):1171-8. PubMed ID: 19716598
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparable spirometric efficacy of tiotropium compared with salmeterol plus fluticasone in patients with COPD: a pilot study.
    Bateman ED; van Dyk M; Sagriotis A
    Pulm Pharmacol Ther; 2008; 21(1):20-5. PubMed ID: 17118684
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Roflumilast--an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial.
    Rabe KF; Bateman ED; O'Donnell D; Witte S; Bredenbröker D; Bethke TD
    Lancet; 2005 Aug 13-19; 366(9485):563-71. PubMed ID: 16099292
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of ADRB2 polymorphisms on the efficacy of salmeterol and tiotropium in preventing COPD exacerbations: a prespecified substudy of the POET-COPD trial.
    Rabe KF; Fabbri LM; Israel E; Kögler H; Riemann K; Schmidt H; Glaab T; Vogelmeier CF
    Lancet Respir Med; 2014 Jan; 2(1):44-53. PubMed ID: 24461901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A pilot study to assess the effects of combining fluticasone propionate/salmeterol and tiotropium on the airflow obstruction of patients with severe-to-very severe COPD.
    Cazzola M; Andò F; Santus P; Ruggeri P; Di Marco F; Sanduzzi A; D'Amato M
    Pulm Pharmacol Ther; 2007; 20(5):556-61. PubMed ID: 16914336
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of roflumilast in patients with stable chronic obstructive pulmonary disease: a meta-analysis.
    Yan JH; Gu WJ; Pan L
    Pulm Pharmacol Ther; 2014 Feb; 27(1):83-9. PubMed ID: 23624309
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of roflumilast in COPD patients receiving inhaled corticosteroid/long-acting β2-agonist fixed-dose combination: RE(2)SPOND rationale and study design.
    Rennard SI; Martinez FJ; Rabe KF; Sethi S; Pizzichini E; McIvor A; Siddiqui S; Anzueto A; Zhu H
    Int J Chron Obstruct Pulmon Dis; 2016; 11():1921-8. PubMed ID: 27574416
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Roflumilast: in chronic obstructive pulmonary disease.
    Sanford M
    Drugs; 2010 Aug; 70(12):1615-27. PubMed ID: 20687624
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Roflumilast: a phosphodiesterase-4 inhibitor for the treatment of severe chronic obstructive pulmonary disease.
    Pinner NA; Hamilton LA; Hughes A
    Clin Ther; 2012 Jan; 34(1):56-66. PubMed ID: 22284994
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tiotropium versus salmeterol for the prevention of exacerbations of COPD.
    Vogelmeier C; Hederer B; Glaab T; Schmidt H; Rutten-van Mölken MP; Beeh KM; Rabe KF; Fabbri LM;
    N Engl J Med; 2011 Mar; 364(12):1093-1103. PubMed ID: 21428765
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phosphodiesterase-4 inhibitors for chronic obstructive pulmonary disease.
    Janjua S; Fortescue R; Poole P
    Cochrane Database Syst Rev; 2020 May; 5(5):CD002309. PubMed ID: 32356609
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison between inhaled salmeterol and theophylline in the short-term treatment of stable chronic obstructive pulmonary disease.
    Broseghini C; Testi R; Polese G; Tosatto R; Rossi A
    Pulm Pharmacol Ther; 2005; 18(2):103-8. PubMed ID: 15649852
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Benefits of adding fluticasone propionate/salmeterol to tiotropium in moderate to severe COPD.
    Hanania NA; Crater GD; Morris AN; Emmett AH; O'Dell DM; Niewoehner DE
    Respir Med; 2012 Jan; 106(1):91-101. PubMed ID: 22040533
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Roflumilast in chronic obstructive pulmonary disease: evidence from large trials.
    Cazzola M; Picciolo S; Matera MG
    Expert Opin Pharmacother; 2010 Feb; 11(3):441-9. PubMed ID: 20102307
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials.
    Decramer M; Anzueto A; Kerwin E; Kaelin T; Richard N; Crater G; Tabberer M; Harris S; Church A
    Lancet Respir Med; 2014 Jun; 2(6):472-86. PubMed ID: 24835833
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical profile of roflumilast].
    Izquierdo Alonso JL
    Arch Bronconeumol; 2010 Dec; 46 Suppl 10():25-32. PubMed ID: 21316553
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-inflammatory effects of roflumilast in chronic obstructive pulmonary disease (ROBERT): a 16-week, randomised, placebo-controlled trial.
    Rabe KF; Watz H; Baraldo S; Pedersen F; Biondini D; Bagul N; Hanauer G; Göhring UM; Purkayastha D; Román J; Alagappan VKT; Saetta M
    Lancet Respir Med; 2018 Nov; 6(11):827-836. PubMed ID: 30224319
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.